Promatrix® announces its first U.S. product launch with a breakthrough patent pending hormonal dietary supplement Primobolan® Acetate orals.
“For immediate release”
Promatrix® announces its first U.S. product launch with a breakthrough patent pending hormonal dietary supplement Primobolan® Acetate orals.
Promatrix® is a leading biotechnology company in the field of the metabolic nutrition associated with hormonal response and human performance, which is dedicated to develop, manufacture, and market approved and clinically effective nutraceuticals that address significant human performance needs.
“We are extremely optimistic that Promatrix® will become a predominant entity in the sports supplement market. We feel this way not only because of Primobolan® but because of our dedication to nutraceutical research,” said Sal Abraham M.S. R.D., Dir. of Research & Patent Development.
Primobolan® Acetate is a hormonal analog of a naturally occurring substance found in the human body. It is designed to inhibit estrogen formation while simultaneously promoting the natural production of total and active testosterone. Primobolan® Acetate primarily functions as an aromatase inhibitor thus inhibiting estrogen formation and stimulating natural testosterone production. The stimulation of total and free testosterone promotes muscle mass, strength, and recovery while the inhibition of estrogen may contribute to fat loss and muscle hardening.
Individuals who can benefit from this compound include anyone interested in altering their physique and athletic performance. This compound may also be utilized by pro-hormone or non pro-hormone users. This new patent pending compound is truly an essential supplement for anyone concerned with physique, strength, recovery and libido enhancements.
Sal Abraham M.S. R.D.
Dir. of Research & Patent Development
200 N. Church Rd.
Franklin, NJ 07416
Email: info@Primobolan.com
Web site: http://www.Primobolan.com
Phone: 1-877-628-7499
05/08/02
001
This article courtesy of http://bouldertrailrunners.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.